Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/24/2025 | $280.00 → $328.00 | Neutral → Overweight | Analyst |
| 11/12/2024 | Peer Perform → Underperform | Wolfe Research | |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 8/16/2024 | $198.00 → $370.00 | Neutral → Buy | Goldman |
| 2/16/2024 | $173.00 | Buy → Neutral | Goldman |
| 2/15/2024 | Peer Perform | Wolfe Research | |
| 12/8/2023 | $171.00 | Equal Weight | Wells Fargo |
| 12/8/2023 | Equal Weight | Wells Fargo |
DEFA14A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
DEF 14A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
144 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
− Novel Mechanism of Action Delivers Rapid Knockdown of Transthyretin, Addressing the Disease at its Source – − Proven Consistency of Effect on Cardiovascular Outcomes, Function, and Quality of Life in ATTR-CM Population Representative of Today's Patients – – Only Therapeutic Approved in the U.S. to Address Both Cardiomyopathy and Polyneuropathy Manifestations of ATTR Amyloidosis − – Alnylam Offers Multiple Programs to Support Broad and Seamless Patient Access; Majority of Patients Expected to Pay $0 in Out-of-Pocket Costs for AMVUTTRA – – Alnylam to Host Conference Call Today at 6:00 pm ET – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today anno
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025 at 3:00 pm ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event. About Alnylam Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ:ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent d
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company's Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnylam Scientific Advisory Board. "Phil helped pioneer the RNAi revolution, sparking the scientific collaboration that led to Alnylam's founding and the development of a transformative new class of medicines," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "He has provided invaluable guidance over the past twenty-two years that has
− Novel Mechanism of Action Delivers Rapid Knockdown of Transthyretin, Addressing the Disease at its Source – − Proven Consistency of Effect on Cardiovascular Outcomes, Function, and Quality of Life in ATTR-CM Population Representative of Today's Patients – – Only Therapeutic Approved in the U.S. to Address Both Cardiomyopathy and Polyneuropathy Manifestations of ATTR Amyloidosis − – Alnylam Offers Multiple Programs to Support Broad and Seamless Patient Access; Majority of Patients Expected to Pay $0 in Out-of-Pocket Costs for AMVUTTRA – – Alnylam to Host Conference Call Today at 6:00 pm ET – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today anno
− Achieved Fourth Quarter and Full Year 2024 Global Net Product Revenues of $451 Million and $1,646 Million, Respectively, Representing 30% and 33% Growth Compared to Same Periods in 2023 – − Supplemental NDA for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy Accepted by FDA, with March 23, 2025 PDUFA Date – − Reiterates Product Sales and Profitability Guidance and Provides Additional 2025 Financial Guidance – − Company to Host and Webcast R&D Day on February 25, 2025 – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2024
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2024 on Thursday, February 13, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2024 results as well as expectations for the future via conference call on Thursday, February 13, 2025 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the
Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-7) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 04/29/2024. Application Category: NDA, Application Number: 212194, Application Classification: Labeling
Submission status for ALNYLAM PHARMS INC's drug OXLUMO (SUPPL-4) with active ingredient LUMASIRAN SODIUM has changed to 'Approval' on 09/19/2023. Application Category: NDA, Application Number: 214103, Application Classification: Labeling
Submission status for ALNYLAM PHARMS INC's drug AMVUTTRA (SUPPL-2) with active ingredient VUTRISIRAN has changed to 'Approval' on 02/16/2023. Application Category: NDA, Application Number: 215515, Application Classification: Labeling
Analyst upgraded Alnylam Pharma from Neutral to Overweight and set a new price target of $328.00 from $280.00 previously
Wolfe Research downgraded Alnylam Pharma from Peer Perform to Underperform
Scotiabank initiated coverage of Alnylam Pharma with a rating of Sector Outperform
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company's Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnylam Scientific Advisory Board. "Phil helped pioneer the RNAi revolution, sparking the scientific collaboration that led to Alnylam's founding and the development of a transformative new class of medicines," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "He has provided invaluable guidance over the past twenty-two years that has
As former leader of Pfizer's infant nutrition and consumer healthcare businesses, Schulman brings extensive experience in the space, in addition to serving on the boards of several biotech and pharmaceutical companies; This marks ByHeart's first non-executive Board chair appointment In addition to Schulman, ByHeart appoints Niall Mullane, PhD, as Chief Quality Officer to join the experienced executive team; Mullane brings 15 years of quality and food safety experience in the infant nutrition category NEW YORK, March 5, 2024 /PRNewswire/ --Today, ByHeart, the next-generation baby nutrition company, announced the appointment of Amy Schulman, managing partner at Polaris partners, as Chair of th
– Experienced Business and Financial Leader, Kellogg Served as Chief Financial Officer at Biogen, Merck, and Celgene – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience. "Mr. Kellogg joins our Board at a pivotal moment for Alnylam as we continue on the path to achieving our P5x25 strategy and fulfilling our ambition to become a top-tier biopharmaceutical company," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "His financial expertise and experi
SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)